Carotid Endartectomy vs Carotid Artery Stenting — quantifying stenosis, comparing surgical and endovascular technique, and weighing perioperative stroke/MI trade-offs
Every carotid revascularization decision begins with an accurate measurement of luminal narrowing. Duplex ultrasound, CT angiography (CTA), and MR angiography (MRA) each estimate percent diameter stenosis using validated criteria (NASCET method), and the resulting number — together with whether the patient has had a recent ipsilateral stroke or TIA — determines whether intervention is even on the table.
Percent stenosis is not a single, universally agreed number — two methodologies dominate the literature:
NASCET method (North American Symptomatic Carotid Endarterectomy Trial): • % stenosis = (1 − [narrowest residual lumen diameter / diameter of normal distal ICA]) × 100 • Uses the distal internal carotid artery (beyond the bulb) as the reference — this became the de facto US/global standard
ECST method (European Carotid Surgery Trial): • Uses the estimated original diameter of the carotid bulb itself as the reference • Produces systematically higher percentages than NASCET for the same lesion
Duplex ultrasound (first-line, non-invasive): • Grey-scale B-mode for plaque morphology (echolucent = lipid-rich/unstable; echogenic = calcified/stable) • Peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the ICA correlate with % diameter stenosis • ICA PSV >230 cm/s + ICA/CCA ratio >4 → suggests ≥70% stenosis (Society of Radiologists in Ultrasound consensus criteria)
CTA and MRA: • Provide 3-D anatomic detail — arch configuration, tortuosity, calcification burden, intracranial run-off — critical for planning either approach • CTA is generally preferred pre-procedurally for CAS to assess aortic arch type and vessel access
A stenosis measured at 60% by ECST criteria may only be ~40% by NASCET criteria on the very same lesion — always confirm which convention a report uses before acting on a number.
Whether a patient is "symptomatic" (ipsilateral TIA, amaurosis fugax, or non-disabling stroke within the prior 6 months) fundamentally changes the risk-benefit calculation:
• Symptomatic + ≥50% stenosis: NASCET showed absolute stroke risk reduction of ~17% at 2 years with CEA vs. medical therapy for 70–99% stenosis, and a smaller but still significant benefit for 50–69% stenosis • Symptomatic patients should be treated urgently — benefit of CEA is greatest within 2 weeks of the qualifying event, and falls off sharply thereafter • Asymptomatic + ≥70% stenosis: ACAS and ACST trials showed a smaller absolute benefit (~1%/yr stroke risk reduction), meaning perioperative complication rates must be kept very low (<3%) for intervention to be worthwhile • With modern intensive medical therapy (high-intensity statins, antiplatelets, BP control), some asymptomatic patients now do nearly as well without intervention — patient selection has become more individualized
Carotid endarterectomy has been the gold-standard treatment for carotid stenosis since the landmark NASCET and ACAS trials of the 1990s. Under general or regional anesthesia, the surgeon exposes the carotid bifurcation, opens the artery directly, and physically peels the plaque away from the vessel wall — restoring a smooth luminal surface.
1. Exposure: a longitudinal incision along the anterior border of the sternocleidomastoid muscle exposes the common (CCA), internal (ICA), and external (ECA) carotid arteries. The vagus and hypoglossal nerves are carefully identified and preserved.
2. Systemic heparinization: intravenous heparin is given before clamping to prevent thromboembolism.
3. Cross-clamping: vascular clamps are sequentially applied to the CCA, ICA, and ECA to isolate the segment. Cerebral perfusion during clamping depends on collateral flow via the circle of Willis.
4. Neuromonitoring / shunt decision: EEG, stump pressure measurement, transcranial Doppler, or awake neurological testing (under regional anesthesia) assess whether collateral flow is adequate. If not, a temporary intraluminal shunt is placed to maintain cerebral perfusion during the repair.
5. Arteriotomy: a longitudinal incision is made in the CCA, extending across the bifurcation into the ICA, exposing the plaque.
6. Endarterectomy: the surgeon develops a plane in the media, and the atheromatous plaque — often a well-defined cylindrical core — is dissected free and removed en bloc, feathering the distal endpoint to avoid a flow-limiting intimal flap.
7. Closure: primary closure or, more commonly, patch angioplasty (Dacron, PTFE, or autologous vein) to widen the lumen and reduce restenosis risk.
8. Completion imaging: duplex ultrasound or angiography confirms a widely patent repair before closing the neck incision.
Patch closure reduces the risk of both perioperative occlusion and late restenosis compared with primary closure, and is now used in the large majority of elective CEAs.
CEA can be performed under general anesthesia (GA) or regional/local anesthesia (cervical block) with the patient awake for continuous neurological monitoring — the GALA trial found no significant difference in stroke, MI, or death between the two approaches, so the choice is largely surgeon/patient preference.
Cranial nerve injury is a recognized, usually transient, complication (~5% of cases): the hypoglossal nerve (tongue deviation), vagus/recurrent laryngeal nerve (hoarseness), marginal mandibular branch of the facial nerve (lip droop), and glossopharyngeal nerve (swallowing difficulty) all run near the surgical field.
Carotid artery stenting offers a minimally invasive alternative to open surgery, delivering a self-expanding stent across the stenotic lesion via a catheter introduced from the femoral artery (transfemoral CAS) or directly through a small neck incision into the common carotid (transcarotid artery revascularization, TCAR). An embolic protection device is used in nearly all cases to capture debris dislodged during the procedure.
1. Vascular access: a sheath is placed in the common femoral artery (transfemoral) or directly in the common carotid artery via a small supraclavicular incision (TCAR).
2. Arch and vessel navigation: a guidewire and guiding catheter are advanced under fluoroscopic road-mapping through the aortic arch into the common carotid artery — arch anatomy (Type I/II/III, bovine arch) determines difficulty.
3. Embolic protection deployment: a distal filter device is advanced across the lesion and opened in the distal ICA to catch plaque debris; alternatively, TCAR uses flow reversal — blood is diverted from the CCA out through a venous return line, so debris flows away from the brain rather than toward it.
4. Pre-dilation: a small balloon may be inflated across the lesion to facilitate stent passage.
5. Stent deployment: a self-expanding nitinol stent (open- or closed-cell design) is deployed across the stenosis, conforming to vessel geometry as it expands.
6. Post-dilation: a balloon is inflated within the stent to optimize apposition and residual lumen, temporarily inducing bradycardia/hypotension via carotid baroreceptor stimulation (atropine often pre-treated).
7. Retrieval: the embolic protection device is withdrawn (loaded with captured debris), and completion angiography confirms stent position and flow.
Baroreceptor stimulation during balloon angioplasty of the carotid bulb can cause profound bradycardia and hypotension — anticipatory atropine and careful hemodynamic monitoring are standard practice during CAS.
Transcarotid artery revascularization (TCAR) was developed specifically to reduce the stroke risk associated with navigating a wire and catheter through a diseased, tortuous aortic arch (the dominant source of embolic stroke in transfemoral CAS). By accessing the CCA directly and establishing high-rate flow reversal before crossing the lesion, TCAR avoids arch manipulation entirely and has shown stroke/death rates approaching those of CEA in registry data (ROADSTER trials), while retaining the minimally invasive, local-anesthesia profile of an endovascular procedure.
Neither CEA nor CAS is universally superior — the optimal choice depends on an individualized assessment of surgical risk, vascular anatomy, age, and prior neck history. Multidisciplinary decision-making (vascular surgery, neurology, interventional cardiology/radiology) increasingly guides this choice on a patient-by-patient basis.
• Older age (particularly ≥70 years) — CREST and pooled trial data show CAS periprocedural stroke risk rises disproportionately with advancing age, while CEA risk stays comparatively flat • Standard surgical risk — no severe cardiac, pulmonary, or renal comorbidity precluding general/regional anesthesia • Anatomically favorable neck — no prior neck surgery, radiation, or radical dissection distorting tissue planes • Heavily calcified or very tortuous cervical carotid anatomy — can make stent delivery and apposition difficult • Unfavorable aortic arch (Type II/III, bovine configuration) — increases technical difficulty and embolic risk of transfemoral catheter navigation • Lesion with large, soft, echolucent (unstable) plaque — theoretically higher embolization risk during stent manipulation
• High surgical/anesthetic risk — severe coronary artery disease, congestive heart failure, severe COPD, or other conditions that make general anesthesia and open surgery hazardous • Hostile or "redo" neck — prior ipsilateral CEA (restenosis), prior neck radiation (e.g., for head and neck cancer), or prior radical neck dissection, all of which markedly increase CEA complication rates (cranial nerve injury, wound healing) • Contralateral carotid occlusion — historically considered higher-risk for CEA clamping • High cervical or surgically inaccessible lesions (near skull base) • Younger patients with long life expectancy and favorable arch/access anatomy, where minimally invasive recovery is prioritized • Tracheostomy stoma or laryngectomy — open neck surgery is technically difficult/contraindicated
The CREST trial (Carotid Revascularization Endarterectomy versus Stenting Trial, NEJM 2010) remains the pivotal head-to-head randomized comparison. Its central finding reframed the debate: the two procedures have statistically similar long-term composite outcomes, but they fail differently in the perioperative window — CAS trades a higher stroke risk for a lower MI risk, and CEA the reverse.
Stenting requires threading wires, catheters, and the stent delivery system across the diseased carotid bifurcation itself — every manipulation of an atherosclerotic lesion risks dislodging embolic debris downstream into the cerebral circulation. Even with embolic protection filters, new silent ischemic lesions are detectable by diffusion-weighted MRI in a substantial minority of CAS cases (far more often than after CEA), though most are clinically silent. Balloon angioplasty and stent deployment directly disrupt the plaque surface, generating the embolic showers responsible for the excess periprocedural stroke risk — this risk is most pronounced in older patients and those with tortuous, heavily calcified arch anatomy.
CEA is open surgery, typically performed under general anesthesia, with associated hemodynamic stress, fluid shifts, and a longer recovery — all of which increase cardiac demand in a patient population that frequently has concomitant coronary artery disease (carotid and coronary atherosclerosis share risk factors and often coexist). The physiologic stress of surgery, anesthesia induction/emergence, and postoperative pain can precipitate demand ischemia or plaque rupture in vulnerable coronary lesions, explaining the higher periprocedural MI rate observed with CEA relative to the less physiologically stressful, usually locally-anesthetized, CAS procedure.
CREST found that periprocedural MI — although less frequent than stroke — was independently associated with markedly increased long-term mortality, suggesting the two complications should not simply be treated as numerically equivalent when weighing risk.
Current society guidelines (SVS, AHA/ASA, ESVS) converge on a similar message: for average-surgical-risk patients with favorable anatomy, CEA remains the preferred first-line therapy, supported by the longest track record and randomized evidence base. CAS is a well-validated alternative — particularly via TCAR — for patients at high surgical risk, with hostile necks, or unfavorable open-surgical anatomy. Ultimately the decision integrates the stenosis severity and symptom status established in Stage 1, the anatomic and comorbidity factors from Stage 4, and this stroke/MI trade-off — ideally discussed explicitly with the patient as a shared decision.